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OBJECTIVES: Caspofungin was non-inferior to liposomal
amphotericin-B (L-AmB) in a recently conducted double-blind,
randomized clinical trial (RCT) in 1095 hematology/oncology
patients with persistent fever and neutropenia. Fewer patients
developed nephrotoxicity with caspofungin than with L-AmB
(2.6% vs. 11.5%, p < 0.001; Walsh et al., 2004). Based on the
RCT data, cost and consequences of treatment with caspofun-
gin versus L-AmB for empirical therapy of suspected systemic
fungal infection were determined for the German hospital
setting. METHODS: Our model is based on: (i) RCT nephro-
toxicity rates; (ii) prolonged length of hospital stay due to
nephrotoxicity in hematology/oncology patients in Europe (5.3
days, accounting perspective, 95%CI 1.6;9.1, p = 0.004;
Ullmann et al., 2006); and (iii) bottom-up data on direct cost of
hematology/oncology stay per day. Bootstrapping and Monte-
Carlo simulations were performed (SAS 9.1.3, WinBUGS 1.4.1).
Calculations were based on patient-individualized doses per
treatment episode per RCT treatment arm (Caspofungin 13 days;
L-AmB 12.5 days; 70 kg patient), on both, ofﬁcial German price
list, and German high-user hospital antifungal acquisition cost.
RESULTS: The number needed to treat for one patient to be
harmed due to nephrotoxicity for L-AmB versus caspofungin
was 12 (95%CI 8;17). The nephrotoxicity-related prolongation
of hospital stay per patient was 0.48 days (95%CI 0.14;0.88).
Based on ofﬁcial list prices, caspofungin was cost-saving com-
pared to L-AmB. Based on high-user hospital pharmacy acquisi-
tion cost and cost from longer stay in hospital due to L-AmB
nephrotoxicity, caspofungin was cost-saving at hospital cost per
day of ≥€670, and ≥€1060, respectively, with and without
“Zusatzentgelt” (2006), a partial compensation German hospi-
tals can apply for to cover cost of caspofungin and L-AmB.
CONCLUSIONS: This model provides a framework for hospi-
tal-based economic evaluations of two different antifungal
agents with respect to tolerability and length of hospital stay.
Such evaluations can improve the quality of medical care and
help to thoughtfully allocate resources.
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OBJECTIVE: Chronic Hepatitis B (CHB) can lead to cirrhosis
and hepatocellular carcinoma. This study aims to estimate
resource utilisation (RU) and costs associated with CHB 
management in Sweden, from a health-system perspective.
METHODS: Medical management patterns were estimated for:
Chronic Hepatitis B (CHB), Compensated Cirrhosis (CC),
Decompensated Cirrhosis (DC), and Hepatocellular Carcinoma
(HC). Resources considered were physician visits, drug therapy,
lab tests, diagnostic/therapeutic procedures and hospitalisation.
RU data were obtained from a Delphi panel of 5 hospital spe-
cialists. Complications considered for DC were: ascites, variceal
haemorrhage, hepatic encephalopathy, and bacterial peritonitis.
For HC, RU was estimated for the ﬁrst year post identiﬁcation
of the cancer. Based on RU, 2005 direct costs were estimated per
health state. RESULTS: Resource utilisation increased across
disease states, reﬂecting disease progression. The average annual
cost (range) of each state was: CHB: SEK 8001 (SEK 1891—SEK
17,011); CC: SEK 34,649 (SEK 7378—SEK 93,185); DC: SEK
135,783 (SEK 20,171—SEK 442,785); HC: SEK 280,009 (SEK
52,759—SEK 619,031); Average LT cost was SEK 668,027. Hos-
pitalisation is a key cost driver in DC and HC states. No GP
visits were reported. Hospital admissions were unneeded in the
CHB state. For CC, 5.8% of patients needed 1.25 admissions
(average 0.08) and in DC, 68% needed 2 admissions (average
1.4). In HC state, all patients were admitted on average 3.4
times. Average LOS in DC and HC states was 11 days. 35% of
HC patients needed hospice admission with an average LOS of
38 days. Common procedures include paracentesis (60%), scle-
rotherapy (50%), and TIPS (30%) in the DC state, and para-
centesis (70%), radiofrequency ablation (15%), and ethanol
injection (10%) in HC. CONCLUSIONS: RU and costs increase
with disease progression: costs for the HC state are more than
30 times those for the CHB stage.
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OBJECTIVE: To assess, in a real life setting, the predictive valid-
ity of a health-economic model that had been applied for the
Belgian reimbursement submission of voriconazole in proven
and probable invasive aspergillosis. METHODS: An observa-
tional study was designed to prospectively collect health-eco-
nomic data of patients with invasive aspergillosis starting
treatment with voriconazole. The same direct costs as in the
model were considered: costs for hospital stay, diagnostic pro-
cedures, treatment/monitoring of side effects, outpatient care and
use of anti-fungal drug(s). Resource utilization, expressed in
physical units, was multiplied with unit costs from the public
payer’s perspective. Costs were expressed as total costs and costs
for switchers/non-switchers from initial voriconazole treatment.
Effectiveness was expressed as clinical response and survival rate
at day 84. RESULTS: A total of 115 patients were included. The
average total cost was €14,153 (C.I.: €11,493; €16,812). This
was below the cost predicted by the model (€21,298). The dif-
ference was mainly caused by shorter hospitalization in this
study (9.59 days) than assumed in the model (29.4 days). On
average the total cost for switchers/non-switchers amounted to
€16,216/€10,067 in this study, which was below the estimated
cost of €27,586/€18,783 in the model, mainly due to a lower
hospitalization cost. The clinical response rate (50% successful
outcome) as well as the infection related survival rate (86.7%)
were in line with the ones applied in the model and reported
from the clinical trials (52% and 87.5% respectively). The
overall survival rate was lower compared to the model (58% vs.
70.8%), likely due to treating patients with poor prognosis at
baseline who would have been excluded from the clinical trial.
CONCLUSIONS: This observational study demonstrated that
the health-economic model provided an overestimate of the real
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life costs with voriconazole and a good estimate of clinical
response and survival rates.
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OBJECTIVES: Routine meningitis C (MenC) vaccination to
individuals <18 years has been adopted in the UK since 1999 but
is not yet available in Germany. Our aim was to estimate the
costs and economic consequences of a routine MenC vaccination
programme in Germany for children aged up to 10 years versus
no vaccination. A secondary analysis considered a catch-up ini-
tiative for individuals aged 11 to 19. METHODS: A published
cohort simulation model was adapted. Data to populate the
model was obtained from published sources and ofﬁcial statis-
tics. Incidence, mortality, and vaccine efﬁcacy were estimated.
Costs included the cost of the vaccination, inpatient manage-
ment, insurance (beneﬁt) payments to parents, and long-term dis-
abilities. Costs were divided by effectiveness (life years gained)
to estimate cost per life year gained. Population estimates were
applied to consider the total cost of vaccination. Selecting cred-
ible data ranges and statistical distributions, a probabilistic sen-
sitivity analysis was performed on ultra-sensitive parameters to
evaluate the effects of multivariate uncertainty and generate 95%
conﬁdence limits. RESULTS: The annual cost of the vaccination
programme was estimated to be €27.2 m, increasing to €59.7 m
when factoring in the catch-up cohort. Managing infections and
long-term costs were estimated to fall by €0.4 m and €0.6 m,
respectively. Routine vaccination was estimated to avoid 6 deaths
per year, increasing to 12 deaths avoided including catch-up.
Findings were sensitive to disease incidence, vaccine efﬁcacy,
mortality and an incidence inﬂator for under-reporting. Cost-
effectiveness was estimated at €64,203 (95% CI: 48,502–
89,246) per life year gained for the primary analysis and €64,865
(51,130—86,412) when including the catch-up initiative. CON-
CLUSIONS: Our results demonstrate a reasonable level of cost-
effectiveness for both vaccination strategies, with a relatively
tractable overall impact on the wider health care system. Results
are broadly similar to those reported in economic evaluations in
other countries.
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OBJECTIVES: Antiviral therapy remains an important treat-
ment strategy for chronic hepatitis B (CHB) in China. However,
multiple antiviral strategies—interferon, lamivudine, adefovir,
and their sequential use—have caused difﬁculties for health deci-
sion-makers in selecting cost-effective treatments, given their
high prices and long-term interventions. This study assessed cost-
effectiveness of current available treatment alternatives for
patients with CHB in China. METHODS: A cost-utility analy-
sis was conducted from the Chinese health care-sector perspec-
tive. We developed a decision-analytic model to simulate a 1-year
disease progression. Markov model was used to simulate life-
time outcomes, based on 1-year results. The model was validated
through discussion with leading hepatologists in China. Seven
treatment alternatives, including no antiviral treatment, were
considered for patients with HBeAg-positive CHB. The data on
disease transition probabilities were primarily obtained from the
randomized trials and meta-analyses, and validated by the clin-
ician expert’s panel. The data on utility of different diseases
states were derived from a published study on Chinese patients.
The resources use was obtained from a literature, and adjusted
based on the expert panel’s recommendations. The unit prices of
resources 2006 were obtained from national and provincial reg-
istries. The costs were presented in US dollars. A rate of 5% was
used to discount the costs. RESULTS: The base-case analysis
showed that, of these seven treatment options, no antiviral
therapy was dominated by all the antiviral treatment options.
Interferon-adefovir sequential use dominated all the other alter-
ative antiviral treatments, with US$562.3 per QALY gained
(US$15215.8 for 27 QALYs). When the transition probability of
HBeAg seroconversion in patients using adefovir was less than
0.157, and that of relapse rate higher than 0.032, lamivudine-
adefovir strategy would be the dominant one. CONCLUSIONS:
Interferon-adefovir appeared to be the most cost-effective strate-
gies for CHB in China. However, clinical effects of adefovir
might affect the robustness of results.
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OBJECTIVES: To estimate the cost-effectiveness of mass-
vaccination with an oral rotavirus vaccine (RIX4414) compared
to no vaccination from a societal perspective. METHODS: A
Markov model was constructed for a hypothetical birth cohort,
comparing two treatment arms, one receiving the vaccine, the
other receiving standard care. In the model, seasonality of the
virus, protection from breastfeeding, and nosocomial infections
are taken into account. Direct medical costs and costs due to loss
of productivity (of the parents) were estimated. Effects were
expressed as the number of hospitalisations, GP visits, deaths,
nosocomial infections, and the quality adjusted life years
(QALYs) over a lifetime horizon. Costs and QALYs were com-
bined into an incremental cost-effectiveness ratio (ICER). Data
for the model were obtained from published local data on inci-
dence of rotavirus infection and consequential health care con-
sumption and from clinical studies measuring the effectiveness
of the vaccine. Costs and effects were discounted at 4% and
1.5%, respectively. A probabilistic sensitivity analysis was per-
formed. RESULTS: Mass-vaccination with RIX4414 shows a
reduction in the number of GP consultations by 95.8%. Hospi-
talisations, nosocomial infections and deaths were reduced with
100%. This results in savings of €8.9 million for direct medical
costs and of approximately €1 million for productivity costs,
whereas the costs of vaccination are estimated at €16.5 million.
Furthermore, 270 QALYs are gained, yielding an ICER of
approximately €24,000. Sensitivity analysis shows that the prob-
ability for nosocomial infection and the probability of hospital-
isation have the largest effect on the outcome. However, the
prioritisation of the alternatives does not alter. CONCLUSIONS:
Mass-vaccination against rotavirus disease with RIX4414 may
be considered economically attractive from a societal perspec-
tive, given the favourable balance between costs and effects,
especially considering the very low health care utilisation in the
Netherlands compared to other European countries.
